Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

370
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
1.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

The New England journal of medicine·2025
Same author

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates.

JCO oncology practice·2025
Same author

Erratum: Current and Novel Treatment Options in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

JCO oncology practice·2025
Same author

EPR25-121: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients: Testing and Referral Guidelines.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study.

JCO global oncology·2024

Related Experiment Video

Updated: May 5, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K

Developing oncology biosimilars: an essential approach for the future.

Jame Abraham1

  • 1Director of Breast Oncology Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Seminars in Oncology
|November 26, 2013
PubMed
Summary
This summary is machine-generated.

Biosimilars offer a promising avenue to increase patient access to vital biologic therapies, particularly in oncology. These advanced biologic drugs are designed to be highly similar to existing treatments, aiming to reduce healthcare costs.

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

7.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Related Experiment Videos

Last Updated: May 5, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

7.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Area of Science:

  • Biotechnology
  • Oncology
  • Pharmaceutical Sciences

Background:

  • Biologic therapies have transformed disease treatment, especially cancer, and are standard in oncology guidelines.
  • Biologics are complex, large-molecule proteins manufactured through intricate processes.
  • Patent expirations for key biologics are driving the development of biosimilars.

Purpose of the Study:

  • To discuss the development and implications of biosimilars in oncology.
  • To differentiate biosimilars from generic small-molecule drugs.
  • To highlight the role of biosimilars in improving patient access and reducing healthcare costs.

Main Methods:

  • Review of biologic therapy landscape in oncology.
  • Analysis of biosimilar development principles.
  • Examination of regulatory and economic factors influencing biosimilar adoption.

Main Results:

  • Biosimilars are highly similar, not identical, to reference biologics due to inherent complexity.
  • Biosimilars are distinct from generic drugs, which are identical small molecules.
  • The development of biosimilars is a strategic response to expiring biologic patents.

Conclusions:

  • Biosimilars are crucial for enhancing patient access to advanced cancer therapies.
  • The integration of biosimilars is expected to significantly reduce healthcare expenditures.
  • Understanding the unique nature of biosimilars is key for their successful clinical implementation.